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Abstract
Adaptation of PB2 protein is important for the establishment of avian influenza viruses in mammalian hosts. Here, we identify 
I292V as the prevalent mutation in PB2 of circulating avian H9N2 and pandemic H1N1 viruses. The same dominant PB2 muta-
tion is also found in most human isolates of emergent avian H7N9 and H10N8 viruses. In human cells, PB2-292V in H9N2 virus 
has the combined ability of conferring higher viral polymerase activity and stronger attenuation of IFN-β induction than that 
of its predecessor PB2-292I. IFN-β attenuation is accompanied by higher binding affinity of PB2-292V for host mitochondrial 
antiviral signalling protein, an important intermediary protein in the induction of IFN-β. In the mouse in vivo model, PB2-292V 
mutation increases H9N2 virus replication with ensuing increase in disease severity. Collectively, PB2-292V is a new mam-
malian adaptive marker that promotes H9N2 virus replication in mammalian hosts with the potential to improve transmission 
from birds to humans.
InTRoduCTIon
Avian H9N2 influenza viruses circulate worldwide and are 
endemic in terrestrial avian species [1, 2]. Sporadically, they 
are transmitted to mammalian species, including humans and 
pigs [3, 4]. Recently, Li et al. found that the H9N2 viruses 
isolated between 2009 and 2013 showed enhanced virulence 
to ferrets and have acquired efficient respiratory droplet 
transmission between ferrets without prior adaptation [5]. 
Based on the World Health Organization data, human cases 
of H9N2 virus infection have also increased in recent years. 
In the previous six years (2013–2018), 33 human cases were 
laboratory-confirmed in China, making up 76 % (33/43) of the 
national H9N2 cases (http://www. who. int/ influenza/ human_ 
animal_ interface/ HAI_ Risk_ Assessment/ en/). Since 2013, 
two novel reassortants, H7N9 and H10N8 viruses, whose 
internal genes were derived from prevailing H9N2 virus, have 
caused regular human infections and prompted serious public 
health concerns [6–8]. Together, current avian H9N2 viruses 
and their reassortants exhibit increasing transmissibility in 
humans, indicating that their shared H9N2-derived internal 
genes are progressively adapting in human replication.
PB2 protein, one of the subunits of the ribonucleoprotein 
(RNP) complex, is a major virulence and host range deter-
minant of influenza viruses [9]. The avian origin PB2 gene 
in influenza viruses generally exhibits restricted polymerase 
activity and impaired virus growth in mammalian hosts 
[9–13]. To overcome this restriction, the avian PB2 gene 
needs to acquire certain mutational changes to improve its 
activity in mammalian cells, as exemplified in PB2-E627K, 
-D701N, -T271A, -K526R and -A588V [10, 14–18]. Addi-
tionally, it was recently reported that PB2 also participates 
in regulating the host innate immune responses through 
inhibiting IFN-β expression [19]. Collectively, these findings 
suggest that the PB2 gene has developed multiple strategies 
to adapt to mammalian hosts.
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Here, we identified I292V mutation in PB2 as a dominant 
genotype in avian H9N2 (since 2010), and in emergent H7N9 
and H10N8 viruses; human isolates of such viruses frequently 
contain the I292V PB2 genotype. Furthermore, the amino 
acid residue PB2-292V is predominant in pandemic (pdm) 
H1N1 human viruses. The PB2-I292V in H9N2 virus confers 
increased replication and more severe pathogenicity to mice 
through enhancing viral polymerase and strong attenuation of 
IFN-β induction. Therefore, PB2-I292V is a newly identified 
mammalian adaptive determinant of avian H9N2 influenza 
viruses.
METHodS
Viruses, plasmids and cells
A/chicken/Shandong/lx1023/2007 (Lx1023) (H9N2) virus 
was isolated from diseased chickens in Shandong, China, in 
October 2007. The virus was propagated in 9- to 11-day-old 
specific pathogen-free (SPF) embryonated chicken eggs. 
pcDNA-PB2, pcDNA-PB1, pcDNA-PA and pcDNA-NP 
expression plasmids of H9N2 were generated by subcloning 
the corresponding coding segment into pcDNA3.1 vector. 
pRK5-Flag-MAVS was generated by subcloning the human 
mitochondrial antiviral signalling (MAVS) cDNA into 
pRK5-Flag.
Human embryonic kidney (293T), Madin–Darby canine 
kidney (MDCK), human lung adenocarcinoma epithelial 
(A549) and chicken fibroblast (DF-1) cells were cultivated in 
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) 
supplemented with 10 % fetal bovine serum, 100 units ml−1 
of penicillin and 100 µg ml−1 of streptomycin. All cell cultures 
were kept at 37 °C and 5 % CO2.
Polymerase activity assay
A dual-luciferase reporter assay system (Promega, Madison, 
WI, USA) was used to compare the polymerase activities 
of viral RNP complexes. The PB2, PB1, PA and NP gene 
segments of wild-type viruses and the mutated PB2 gene 
were cloned into the pcDNA3.1 expression plasmid. The 
PB2, PB1, PA and NP plasmids (125 ng each plasmid) were 
used to transfect 293 T or DF1 cells, together with a pYH-
NS1-Luci plasmid expressing a reporter firefly luciferase gene 
under the control of the human or chicken RNA polymerase I 
promoter (10 ng), and an internal control plasmid expressing 
Renilla luciferase (2.5 ng). Cultures were incubated at 33, 37 
or 39 °C. Cell lysates were analysed 24 h after transfection to 
measure firefly and Renilla luciferase activities using GloMax 
96 microplate luminometer (Promega).
IFn-β assay
The 293T cells in 24-well plates were transfected with 200 
ng of IFN-β firefly luciferase plasmid, 20 ng Renilla lucif-
erase internal control plasmid, and 400 ng of the influenza 
virus PB2-expressing plasmid, GFP-expressing plasmid or 
pcDNA3.1 vector. At 18 h post transfection, 293T cells were 
inoculated with Sendai virus to activate the IFN-β signalling. 
The cells were incubated for 18 h and then lysed in 100 µl 
of passive lysis buffer (PLB; Promega). Firefly and Renilla 
luciferase activities were assessed using a Dual-Luciferase 
Assay Kit (Promega).
To determine the effect of PB2 protein on the expression of 
IFN-β mRNA, 293T cells in 24-well plates were transfected 
with 400 ng of the influenza virus PB2-expression plasmid, 
GFP-expressing plasmid or pcDNA3.1 vector. At 18 h post 
transfection, 293T cells were infected with Sendai virus to 
activate the IFN-β signalling. Total RNA was extracted from 
transfected 293T cells at 18 h post inoculation (h p.i.). To 
measure the levels of IFN-β expression during inﬂuenza 
virus infection, A549 cells were infected with H9N2 viruses 
at an m.o.i. of 2. Total cellular RNA was isolated using the 
TRIzol reagent (Invitrogen) at 12 and 24 h p.i. Total RNA 
from transfected 293T cells or influenza virus infected A549 
cells was reverse transcribed using SuperScript II (Invitrogen) 
and oligo dT primer. The qRT-PCR mixture for each reaction 
sample consisted of 10 µl of 2×SYBR green PCR master mix 
(Applied Biosystems), 7 µl of nuclease-free water, 0.5 µl of 
each primer and 2 µl of cDNA template. Expression of IFN-β 
was quantified using the 7500 real-time PCR system (Applied 
Biosystems) and data was analysed using the 2–△△CT method. 
Each experiment comprised three technical replicates for each 
sample, and three experimental replicates were performed.
Western blotting
Total cell protein lysates were extracted from 293T cells 
with RIPA lysis buffer and total protein concentration was 
determined by a BCA protein assay kit (Beyotime, China). 
Protein samples derived from cell lysates were heated at 
100 °C for 10 min and then separated on a 10 % sodium 
dodecyl sulfate-polyacrylamide (SDS-PAGE) gel and trans-
ferred to a polyvinylidene difluoride (PVDF) membrane 
(Bio-Rad, USA), and subsequently incubated with the 
appropriate primary antibody. Primary antibodies used were 
for the detection of β-actin (Beyotime, China), Flag (Sigma, 
USA), influenza virus PB2 (ThermoFisher, USA) and GFP 
(Santa Cruz, USA) protein. The secondary antibody used 
was horseradish peroxidase (HRP)-conjugated anti-rabbit 
or -mouse antibody (Beyotime, China). HRP presence was 
detected using a Western Lightning chemiluminescence kit 
(Amersham Pharmacia, Freiburg, Germany), following the 
manufacturer’s protocols.
Immunoprecipitation assay
The 293T cells were transfected with MAVS and PB2 
expression plasmids and incubated at 37 °C. At 24 h post-
transfection, cells were collected and washed in ice-cold 
PBS. Immunoprecipitation of PB2 protein were performed as 
described previously [20]. In brief, cells were exposed to lysis 
buffer (50 mM Tris-Cl at pH 8.0, 150 mM NaCl, 1 % Triton 
X-100, 1 mM DTT, 1 complete protease inhibitor cocktail and 
10 % glycerol). The clarified cell lysate was used for immuno-
precipitation for 4 h with ANTI-FLAG M2 magnetic beads 
(Sigma). Beads were washed and boiled. Protein samples were 
analysed by Western blotting.
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Generation of recombinant viruses
All eight gene segments amplified by RT-PCR from H9N2 
viruses were cloned into a dual-promoter plasmid, pHW2000. 
Mutation in the PB2 gene was introduced using Site-directed 
Quick Change Mutagenesis kit (Agilent) according to the 
manufacturer's instructions. Primer sequences are available 
upon request. All of the constructs were sequenced to confirm 
the site-directed mutation. Viruses were rescued using the 
eight-plasmid rescue system [21]. Briefly, all eight plasmids 
encoding gene segments were transfected in 293T cells using 
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. After incubation for 6 h at 37 °C, the 
transfection mixture was removed from the cells, and 1 ml of 
Opti-MEM containing 2 µg ml−1 tosylsulfonyl phenylalanyl 
chloromethyl ketone-treated trypsin (TPCK-treated trypsin) 
was added. After 48 h, the harvested cell supernatant was used 
to inoculate 9-day-old SPF chicken embryos to produce stock 
viruses.
Quantitative real-time PCR (qRT-PCR)
Levels of mRNA and vRNA were determined in A549 cells 
infected with H9N2 viruses. Total RNA was extracted from 
infected A549 cells using TRIzol reagent according to the 
manufacturer’s instructions (Invitrogen). For the detection 
of mRNA and vRNA, oligo dT primer and uni-12 primer 
(5′-AGCAAACGACC-3′) were respectively used to generate 
cDNAs from 1 µg of total RNA per sample using Super-
script III First-Strand Synthesis SuperMix (Invitrogen). The 
qRT-PCR mixture for each reaction sample consisted of 10 
µl of 2×SYBR green PCR master mix (Applied Biosystems), 
7 µl of nuclease-free water, 0.5 µl of each primer and 2 µl 
of cDNA template. Expression of mRNA and vRNA of the 
β-actin, matrix protein (M1) and nucleoprotein (NP) genes 
was detected using the 7500 real-time PCR system (Applied 
Biosystems) with the following program: 1 cycle at 95 °C for 
10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C 
for 1 min. Expression values of each gene, relative to β-actin, 
were calculated using the 2–△△CT method. Each experiment 
comprised three technical replicates for each sample, and 
three experimental replicates were performed. Primers 
for amplification of β-actin, M1 and NP genes are listed 
as follows: β-actin, forward, 5′- AGAGCTACGAGCTGC-
CTGAC-3′, reverse, 5′-CGTGGATGCCACAGGACT-3′; 
M1, forward, 5′- CGCACAGAGACTTGAGGATG-3′, 
reverse, 5′- TGGGTCTCCATTCCCATTTA-3′; NP, 
forward, 5′- CAGTGAAGGGGATAGGGACA-3′, reverse, 
5′- CCAGGATTTCTGCTCTCTCG-3′.
Virus titration and replication kinetics
TCID50 was determined in MDCK cells with tenfold serially 
diluted viruses inoculated at 37 °C for 48 h. The TCID50 value 
was calculated by the Reed–Muench method [22]. Multistep 
replication kinetics were determined by inoculating A549 or 
MDCK cells. After 1 h incubation at 37 °C, the cells were 
washed twice and further incubated in serum-free DMEM 
containing 2.0 µg ml−1 TPCK-treated trypsin. Cell superna-
tants were harvested at 12, 24, 36, 48, 60 and 72 h p.i. and 
titrated by inoculating MDCK cells. Each experiment was 
performed in triplicate.
Mouse experiments
Groups of 6-week-old female BALB/c mice (Beijing Experi-
mental Animal Center) were anesthetized with Zoletil 50 
(tiletamine-zolazepam; Virbac S.A., Carros, France; 20 µg 
g−1) and inoculated intranasally with 50 µl PBS or 106 TCID50 
of H9N2 viruses in 50 µl PBS. Five mice from each group 
were monitored daily for 14 days, and mice losing more than 
25 % of their original body weight were humanely euthanized. 
Three mice from each group were euthanized on 3, 5 and 7 
days p.i. for virus titration and histopathology assay. Lungs 
Fig. 1. Prevalence of PB2-I292V in multiple subtypes of influenza viruses. (a) Prevalence of PB2-292V in avian H9N2 influenza viruses 
during the period of 1994–2018. (b) Prevalence of PB2-292V in avian and human H9N2, H7N9, H10N8, avian H1 and human pH1N1 
influenza viruses during the period of 1994–2018. For each column from left to right, the actual number of viruses is 62, 56, 125, 39, 38, 
83, 125, 329, 99, 165, 19, 35 and 4, respectively in (a); 1177, 15, 700, 1287, 46, 5, 85 and 710 in (b). Others refer to viruses without PB2-
292I or -292V. The proportion of viruses with others (0.14 %) is too low to be seen in the third column from left to right (b).
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were collected and homogenized in 1 ml of cold PBS. Virus 
titrer were determined by TCID50. A portion of the lung 
from each euthanized mouse at 5 days p.i. was fixed in 10 % 
phosphate-buffered formalin for histopathological examina-
tion, which was performed as described previously [23].
Statistical analyses
All statistical analyses were performed using GraphPad Prism 
software version 5.00 (GraphPad Software, San Diego, CA, 
USA). Statistically significant differences between experi-
mental groups were determined using ANOVA. Differences 
were considered statistically significant at P<0.05.
RESuLTS
Potential mammalian adaptative mutation of 
PB2-I292V is predominant in avian H9n2 influenza 
viruses
Current avian H9N2 influenza virus and its reassortants 
exhibit a growing trend toward enhanced human infection 
capacity; adaptive mutations of PB2 protein have been demon-
strated to be important in host adaptation [10, 16–18, 24, 25]. 
In this study, sequence analysis of PB2 proteins of H9N2 
avian influenza viruses (AIVs) was performed to identify 
potential mammalian adaptive amino acids. The results 
showed that the H9N2 PB2-292 amino acid residue had 
undergone a shift from I to V over the past 20 years in China 
(Fig. 1a). During the period of 1994–2009, H9N2 viruses with 
PB2-292I were prevalent while viruses with PB2-292V were 
infrequently found. However, the frequency of H9N2 viruses 
with PB2-292V increased sharply from 15.38 % prevalence 
in 2009 to 60.53 % in 2010 to become predominant among 
avian H9N2 viruses. By the end of 2013, viruses possessing 
PB2-292V have become the absolute dominant circulating 
H9N2 (97.69 %) in avian throughout China (Fig. 1a). We 
further compared the prevalence of PB2-292V in H9N2, novel 
H7N9 and H10N8 viruses isolated from avian and human 
hosts (Fig. 1b). PB2-292V was dominantly prevalent in H7N9 
viruses isolated from avian and human hosts, while H9N2 
and H10N8 isolated from humans showed higher frequency 
of PB2-292V than from corresponding avian isolates. In 
addition, we found that PB2-292V was highly conserved in 
human pandemic H1N1 influenza viruses, while H1 influ-
enza subtype isolated from avian species preferred to encode 
PB2-292I. These results indicate that PB2-292V is a potential 
mammalian adaptive amino acid residue, which might facili-
tate virus replication and pathogenicity in humans.
PB2-I292V confers in H9n2 virus higher 
polymerase activity in human cells
PB2 protein is a component of the ribonucleoprotein complex, 
which is responsible for viral polymerase activity and deter-
mines viral infection in new hosts [9, 26]. To identify whether 
PB2-I292V enhances the RNP polymerase activity, viral mini-
genome polymerase assays were performed by transfecting 
wild-type PB2 (PB2-292I) or mutant PB2 (PB2-292V) gene 
encoding plasmid with PB1, PA and NP expression plasmids 
of wild-type H9N2 virus. As shown in Fig. 2a, PB2-I292V 
mutation resulted in significant increase in polymerase 
activity in human 293T cells at both 33 and 37 °C (P<0.05). 
However, in avian DF-1 cells, RNP polymerase activities with 
wild-type and 292V site-mutant PB2 showed no significant 
difference at 37 and 39 °C (Fig. 2b). These results demonstrate 
that PB2-292V is a host species-specific adaptor, which may 
specifically enhance the polymerase activity of H9N2 avian 
inﬂuenza virus in human cells.
PB2-I292V augments transcription and genomic 
RnA replication of H9n2 virus in human cells
vRNP polymerase activity catalyses viral genomic tran-
scription and replication [9]. To ascertain whether vRNP 
polymerase activity is affected by PB2-I292V mutation, 
we produced wild-type (H9N2:PB2-292I), and mutant 
(H9N2:PB2-292V) viruses by reverse genetics. Levels of viral 
mRNA and vRNA in A549 cells infected with wild-type and 
mutant viruses were determined at 2, 6, 12, 24 h p.i. (Fig. 3). 
The results of qRT-PCR showed that H9N2:PB2-292V 
Fig. 2. RNP polymerase activity was higher in the presence of PB2-292V than PB2-292I in human 293T cells. RNP polymerase activities 
of wild-type and mutant viruses in (a) 293T and (b) avian DF1 cells, transfected with polymerase plasmids (PB1, PA, NP and PB2-292I or 
PB2-292V), were determined by mini genome replication assays at different temperatures with reference PB2-292I at 100 %. Data are 
presented as means±sd of three independent experiments. Statistical significance was based on two-way ANOVA (*P<0.05, **P<0.01, 
***P<0.001).
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produced significantly higher levels of both mRNA and vRNA 
of viral M1 and NP than H9N2:PB2-292I at 6, 12 and 24 h 
p.i. (P<0.05), demonstrating that PB2-I292V increases avian 
H9N2 influenza viral transcription and replication in human 
A549 cells.
PB2-I292V mutational change in PB2 strongly 
attenuates virus induced IFn-β expression in 
human cells
PB2 protein was recently demonstrated to interfere with host 
IFN-β antiviral response [19, 27]. We compared the promoter 
response of human IFN-β to Sendai virus infection in the 
presence of PB2-292I and PB2-292V proteins in 293T cells 
(Fig. 4a). Both PB2-292I and PB2-292V significantly reduced 
IFN-β induction with PB2-292V conferring stronger attenu-
ation (P<0.05) (Fig. 4a). In addition, corresponding IFN-β 
mRNA levels were reduced; in the presence of PB2-292V, 
IFN-β expression was 43 % of that of PB2-292I (P<0.05) 
(Fig. 4b). The observed increase in IFN-β inhibition with 
PB2-292V was not due to a difference in PB2 protein produc-
tion as determined by Western blotting (Fig. 4c).
Previous study demonstrated that PB2 protein inhibited the 
expression of IFN-β by interacting with MAVS protein [19]. 
Fig. 3. Avian H9N2 virus with PB2-292V generated more mRNA and vRNA of viral M1 and NP genes than the same virus with PB2-292I. 
A549 cells were infected separately with H9N2:PB2-292I and H9N2:PB2-292V at 0.2 m.o.i. for 2, 6, 12 and 24 h. Normalized mRNA and 
vRNA levels of M1 and NP at each time point are expressed as fold-change relative to H9N2:PB2-292I. Data are presented as means±sd 
of three independent experiments. Statistical significance was based on two-way ANOVA (*P<0.05, **P<0.01, ***P<0.001).
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We next examined the relative binding of PB2-292V and 
PB2-292I to MAVS by co-transfection followed by immu-
noprecipitation (Fig. 4d, e). Both PB2-292I and PB2-292V 
co-immunoprecipitated with Flag-MAVS fusion protein; 
PB2-292V was co-immunoprecipitated at twice the level of 
PB2-292I, demonstrating that PB2-I292V mutation increases 
the binding affinity of PB2 to MAVS.
To further investigate whether the PB2-I292V mutation 
has an effect on the expression of IFN-β mRNA in response 
to influenza virus infection, A549 cells were separately 
infected with H9N2:PB2-292I and H9N2:PB2-292V virus 
and the IFN-β mRNA levels were determined at 12 and 24 
h p.i. (Fig. 4f). IFN-β expression in H9N2:PB2-292V virus 
infected cells was significantly lower than those infected with 
H9N2:PB2-292I virus-infected cells (P<0.05). In summary, 
PB2-292V shows higher binding affinity for MAVS and is 
better at attenuating the induction of IFN-β than PB2-292I 
in H9N2 virus.
PB2-I292V mutation increases replication of H9n2 
virus in mammalian cells
Multicycle growth kinetics of wild-type (PB2-292I) and 
mutant (PB2-292V) H9N2 viruses were determined over 
72 h in A549 and MDCK cells at an m.o.i. of 0.2 and 0.001, 
respectively. Wild-type PB2-292V virus was up to tenfold 
more productive in progeny virus than that of PB2-292I virus 
in A549 cells (P<0.05) (Fig. 5a). In MDCK cells, PB2-292V 
virus was also more productive by about tenfold relative to 
PB2-292I virus at 36, 48 and 60 h p.i. (P<0.01) (Fig. 5b). Thus, 
PB2-I292V H9N2 virus replicates to a higher titre than that 
of PB2-292V virus in mammalian cells.
PB2-292V virus is more replication proficient and 
pathogenic than PB2-292I virus in mice
Groups of mice were inoculated intranasally with PBS or 106 
TCID50 of each virus. During the 14 day period, H9N2:PB2-
292I virus infected mice showed some weight loss of around 
5.01 % at the start of infection with no mortality (Fig. 6a, b). 
Fig. 4. PB2-I292V mutation in avian H9N2 virus strongly attenuated IFN-β induction. (a) 293T cells were co-transfected with a human 
IFN-β promoter-luciferase reporter construct. (a) Renilla luciferase control plasmid, and indicated PB2 expression constructs or 
control GFP-expressing plasmid. At 18 h post-transfection, 293T cells were infected with Sendai virus and dual luciferase assay was 
performed at 18 h p.i. (b) Corresponding IFN-β expression levels normalized to β-actin were determined by qPCR. (c) Protein detection 
of PB2-292I and PB2-292V in 293T cells transfected with corresponding expression constructs. β-actin detection indicated uniform 
protein loading. (d) 293T cells were co-transfected with pRK5-Flag-MAVS, PB2-292I, PB2-292V and control constructs as indicated. 
Cells were lysed 24 h post-transfection and immunoprecipitation was performed with the anti-Flag M2 magnetic beads which showed 
co-immunoprecipitation of PB2 proteins. (e) Densitometry measurements using Image J showed higher co-immunoprecipitation of 
PB2-292V than PB2-292I. Relative reference value of PB2-292I protein was set at 100 %. Data are presented as means±sd of three 
independent co-immunoprecipitation experiments. (f) A549 cells were infected with H9N2:PB2-292I or H9N2:PB2-292V virus at an m.o.i. 
of 2 for 12 and 24 h. Stronger attenuation of IFN-β expression, as determined by qPCR normalized to β-actin, was evident with PB2-292V 
compared with PB2-292I virus. Data are presented as mean±sd of three independent experiments Statistical significance was based on 
two-way ANOVA (*P<0.05, **P<0.01, ***P<0.001).
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H9N2:PB2-292V virus infection caused moderate weight loss 
(up to 20 %) and resulted in death in 1 out of 5 mice (Fig. 6a, 
b). H9N2:PB2-292I infected lungs showed mild changes 
while H9N2:PB2-292V infection resulted in severe pockets 
of interstitial pneumonia, characterized by alveolar interstitial 
consolidation and extensive inflammatory cell infiltration 
(Fig. 6c). Likewise, lung virus titres from PB2-292V virus 
infection were over 400-fold higher than those of PB2-292I 
virus at 3, 5 and 7 days p.i. (Fig. 6d). Collectively, PB2-292V 
in H9N2 virus improves virus replication and causes more 
severe infection in mice.
dISCuSSIon
In this study, we identified a new mammalian adaptive muta-
tion, PB2-I292V, which is highly prevalent in circulating 
Fig. 5. Avian H9N2 virus with PB2-292V replicated more effectively than the same virus with PB2-292I in (a) A549 and (b) MDCK cells. 
Multistep growth curves of H9N2 viruses were determined in A549 and MDCK cells at an m.o.i. of 0.2 and 0.001, respectively. Virus 
titres were determined from supernatants collected at the indicated time points. Data are presented as means±sd of three independent 
experiments. Statistical significance was based on two-way ANOVA (*P<0.05, **P<0.01, ***P<0.001).
Fig. 6. PB2-I292V mutation in H9N2 virus raised pathogenicity and viral replication in mice. Groups of BALB/c mice were inoculated 
with 106 TCID
50 
of the indicated in mice. Groups of BALB/c mice were inoculated with 106 TCID
50
 of the indicated virus or mock infected 
with PBS. (a) Body weight changes of mice inoculated with H9N2:PB2-292I and H9N2:PB2-292V virus. Data are presented as means±sd 
of five individual mice. (b) Survival rates of mice. Mice infected with PB2-292V virus showed higher morbidity than PB2-292I virus. 
Mice with weight loss of more than 25 % were euthanized. (c) Hematoxylin and eosin (H&E) stained lung sections of mice infected with 
indicated virus at 5 days p.i. Scale bar, 200 μm. (d) Virus titres in lungs harvested from three mice per group at 3, 5 and 7 days p.i. Virus 
titres are means±sd of three individual mice. Statistical significance was based on two-way ANOVA (*P<0.05, **P<0.01, ***P<0.001).
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H9N2, its reassortants and pdm H1N1 virus. PB2-292V 
mutation confers increased viral polymerase activity and 
enhanced inhibition of IFN-β induction in human cells. In 
the mouse model, PB2-292V mutation increases H9N2 virus 
replication with ensuing increase in disease severity. These 
findings provide an explanation for increased human infec-
tion cases of avian H9N2 virus and its reassortants.
Increased polymerase activity conferred by other muta-
tions on PB2, such as PB2-E627K, has been shown to 
be crucial for AIVs to adapt to mammalian hosts [10]. 
PB2-627 residue is sited in several functional domains, 
including the NP protein-binding domain and the RNA-
binding domain. PB2-E627K mutation alters polymerase 
activity by affecting the interaction of PB2 with NP [28] and 
exhibits higher binding affinity for RNA, in particular the 5′ 
vRNA promoter [29]. There are PB2 mutations not located 
in any known functional domain but exhibit significant 
mammalian adaptability, such as PA-356 residue [11]. In 
the present study, reside 292 in PB2 is not associated with 
any recognized functional domain, but is in proximity to 
the cap-binding domain [30]. Capped RNA recognition 
by the cap-binding domain of PB2 protein is important in 
the synthesis of viral mRNAs. PB2-I292V mutation could 
conceivably improve cap recognition and promote viral 
replication in human cells.
Interestingly, PB2-292I and PB2-292V mutations in H9N2 
virus show no difference in viral polymerase activity in 
avian cells, suggesting that PB2-I292V mutation specifically 
promotes infectivity in mammalian cells. A similar situation 
is seen with the predominant PA-K356R and HA-Q226L 
mutations in H9N2 virus; they each specifically promote 
mammalian adaptation [11]. Other mutations, such as 
HA-A316S, however, were found to function efficiently in 
both avian and mammalian hosts [31].
Previous studies have demonstrated that growth and 
pathogenicity of influenza virus are influenced by not 
only viral polymerase activity but also host factors [27]. 
Type I IFN is known to be critical to the activation of host 
antiviral responses, and its inhibition leads to enhanced 
viral replication and virulence to host [32]. NS1 protein is 
the first well-characterized influenza viral protein shown 
to antagonize the host innate immune response and is a 
major virulence factor of multiple influenza virus strains 
[33, 34]. Additionally, PB1-F2 protein plays an important 
role in the increased virulence of H5N1 viruses through 
inhibiting the induction of type I IFN [35]. Notably, PB2 
protein has been shown to inhibit IFN-β expression by 
interacting with MAVS [19]. Our results show that in 
human cells, H9N2 virus with PB2-292V mutation has 
the combined features of higher viral polymerase activity 
and stronger attenuation of host IFN-β response. Unlike 
the PB2-I292V mutation reported in the current study, 
the well-known human adaptive mutations of PB2-E627K 
and -D701N [10, 15] are rarely found in prevailing avian 
H9N2 viruses. Along with the propensity of PB2-292V 
mutation in H9N2 virus to reassort to other prevailing 
avian subtypes such as H7N9 and H10N8 viruses, their 
combined threat posed by its presence to human health 
could be significant. It is therefore necessary to closely 
monitor for the presence of PB2-292V, along with other 
known viral markers of virulence, to anticipate major 
outbreaks of severe disease in humans and other suscep-
tible species.
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